These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8100113)

  • 1. [Pharmacokinetics and metabolism of tofizopam (Grandaxin)].
    Klebovich I; Abermann M
    Acta Pharm Hung; 1993 Mar; 63(2):83-90. PubMed ID: 8100113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of metabolites of tofizopam in man and animals.
    Tomori E; Elekes I; Láng T; Horváth G
    Pol J Pharmacol Pharm; 1984; 36(4):423-30. PubMed ID: 6152052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetic study of nerisopam and its n-acetyl metabolite in rats].
    Ary K; Róna K; Renczes G; Gachályi B; Riesz T; Grézal G; Klebovich I
    Acta Pharm Hung; 1997; 67(2-3):59-63. PubMed ID: 9289937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and metabolism of premazepam, a new potential anxiolytic, in humans.
    Vitiello B; Buniva G; Bernareggi A; Assandri A; Perazzi A; Fuccella LM; Palumbo R
    Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):273-7. PubMed ID: 6146571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
    Prakash C; Cui D; Baxter JG; Bright GM; Miceli J; Wilner K
    Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Excerpts from the clinical-pharmacologic and clinical studies of Grandaxin].
    Szegó J; Somogyi M; Papp E
    Acta Pharm Hung; 1993 Mar; 63(2):91-8. PubMed ID: 8100114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
    Prakash C; Soliman V
    Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic fate of premazepam, a new anti-anxiety drug, in the rat and the dog.
    Assandri A; Barone D; Ferrari P; Perazzi A; Ripamonti A; Tuan G; Zerilli LF
    Drug Metab Dispos; 1984; 12(2):257-63. PubMed ID: 6144494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of remoxipride in different species. Species differences in metabolism.
    Widman M; Nilsson LB; Bryske B; Lundström J
    Arzneimittelforschung; 1993 Mar; 43(3):287-97. PubMed ID: 8489555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
    Prakash C; Cui D
    Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of ethyl loflazepate in the rat, the dog, the baboon and in man.
    Davi H; Guyonnet J; Sales Y; Cautreels W
    Arzneimittelforschung; 1985; 35(7):1061-5. PubMed ID: 2864933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and disposition of peptido-aminobenzophenone (2-o-chlorobenzoyl-4-chloro-N-methyl-N-glycylglycinanilide) and its major benzodiazepine metabolites in dogs.
    Konishi M; Agoh T; Sato T; Konaka R; Mori Y
    Drug Metab Dispos; 1980; 8(4):253-9. PubMed ID: 6105060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and toxicokinetics of an orally active tripeptide, IRI-695, in animals.
    Adusumalli V; Corkum N; Jacala A; Mukherjee T; Goodlett D; Crowther J; McConnell I; Goldstein G
    Biopharm Drug Dispos; 1996 Jan; 17(1):25-41. PubMed ID: 8991489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of deramciclane in rabbits.
    Lengyel J; Bojti E; Bolehovszky A; Grézal G; Klebovich I; Magyar K
    Arzneimittelforschung; 1998 Nov; 48(11):1063-8. PubMed ID: 9850425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Human pharmacokinetic study of nerisopam and its n-acetyl metabolite].
    Róna K; Ary K; Renczes G; Gachályi B; Grézal G; Drabant S; Csörgö M; Klebovich I
    Acta Pharm Hung; 1997; 67(2-3):65-71. PubMed ID: 9289938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
    Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
    Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of pinazepam in healthy volunteers.
    Pacifici GM; Placidi GF; Fornaro P; Gomeni R
    Int J Clin Pharmacol Res; 1983; 3(5):331-7. PubMed ID: 6147314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.
    Boberg M; Ahr HJ; Beckermann B; Bühner K; Siefert HM; Steinke W; Wünsche C; Hirayama M
    Arzneimittelforschung; 1997 Aug; 47(8):928-38. PubMed ID: 9296279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption, distribution, elimination and metabolism of tofizopam, a new 2,3-benzodiazepine derivative, in animal experiments.
    Elekes I; Láng T; Csányi E; Horvath G; Körösi J
    Farmaco Prat; 1981 Dec; 36(12):542-52. PubMed ID: 6119228
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.